Prot #CA209-816: Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC

Project: Research project

Project Details

StatusActive
Effective start/end date8/28/178/28/20

Funding

  • Bristol-Myers Squibb Company (Prot #CA209-816)